Acute XXXX , @entity683 vaccination and airway reactivity in @entity565 .

@entity748 @entity1 @entity565 @entity16 @entity2490 @entity281 @entity683 @entity764 @entity1729 @entity112 @entity221
One of the characteristic features of @entity565 is its tendency to become exacerbated during acute infections of the respiratory tract. There are only a few studies on the relation between @entity281 and the exacerbation of @entity565 in adult @entity748 . @entity16 , leading to transient increase in bronchial reactivity, are believed to be some of the mechanisms whereby @entity1729 cause @entity748 exacerbations. A total of 150 @entity1 with @entity565 were studied. Study I, which dealt with the effect of @entity1729 on the exacerbation of @entity565 , comprised 92 @entity748 . The @entity1 evaluated the severity of their disease daily by recording a symptom score in a follow-up chart. Peak expiratory flow (PEF) was measured by the @entity1 with a mini-Wright peak flow meter twice a day. In order to detect @entity1729 , the occurrence of @entity221 , sore throat and symptoms of @entity2490 were also recorded. The daily self-observation by the @entity1 was augmented by monthly examinations by a physician and an interview by a nurse. In the course of study I, 253 episodes of exacerbation of @entity565 were observed in 67 of the 92 @entity1 . 63 (25%) of these 253 exacerbations were found in association with symptomatic @entity1729 (SRI). The mean duration of exacerbations associated with SRI was 11.4 days, significantly longer than the mean duration of 8.1 days of the other exacerbations. A series of 39 @entity1 were entered in study II concerning the effect of vaccination on airway conductance and respiratory symptoms, and 27 @entity748 were assigned to study III which dealt with bronchial reactivity after vaccination with killed @entity683 virus vaccine. Study IV (bronchial reactivity after @entity281 ) comprised 13 @entity1 . 21 members of hospital staff, without a history of @entity764 , participated in studies II and IV as healthy controls. The virus vaccines in studies II, III and IV were provided by the manufacturers. The subjects were seen by the investigators immediately before and 2, 3 and either 14 or 21 days after vaccination. The presence of respiratory symptoms was assessed at each visit. In order to detect changes in respiratory function after vaccination, Raw and ITGV were measured at each visit. The results were expressed as specific airway conductance (SGaw). In studies III and IV, airway reactivity to inhaled @entity112 before and after vaccination was also measured.(ABSTRACT TRUNCATED AT 400 WORDS)
